Titre du document / Document title

Pharmacokinetics of fluconazole in immune-compromised children with leukemia or other hematologic disease

Auteur(s) / Author(s)

SEAY R. E. ⁽¹⁾ ; LARSON T. A. ; TOSCANO J. P. ; BOSTROM B. C. ; O'LEARY M. C. ; UDEN D. L. ;

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

⁽¹⁾ Children's health care-Minneapolis, dep. clin. pharmacy, Minneapolis MN 55404, ETATS-UNIS

Résumé / Abstract

Study Objective. To describe the pharmacokinetics of fluconazole in immunecompromised children with leukemia or other hematologic disease. Design. Prospective. Setting. Childrens Health Care-Minneapolis hematology/oncology inpatient ward and outpatient clinic. Patients. Ten immune-compromised children (mean±SD age 7.4±4.0 yrs, weight 31.6±25.9 kg) with leukemia or other hematologic disease. Interventions. Serum was sampled before and after a single 6-mg/kg intravenous dose and after seven oral 3-mg/kg doses of fluconazole. Measurements and Main Results. Mean (SD) pharmacokinetics were distribution half-life 1.67 (1.25) hours, elimination half-life 15.62 (3.21) hours, total body clearance 0.63 (0.19) ml/min/kg, volume of distribution for the central compartment 0.56 (0.10) L/kg, volume of distribution at steady state 0.77 (0.12) L/kg, absorption half-life 0.41 (0.26) hour, and oral bioavailability 0.92 (0.09). Volume of distribution for the central compartment was highly correlated with body surface area (r²=0.891) and weight (r²=0.949). Volume of distribution at steady state correlated with body surface area (r²=0.986), and total body clearance correlated with body surface area (r²=0.867). Conclusions. Fluconazole elimination was well described using a two-compartment model. Oral absorption was rapid and nearly complete. Children have a larger volume of distribution for the central compartment and faster elimination rate than adults. Body surface area and weight are important factors in determining pharmacokinetics in these patients

Revue / Journal Title

Pharmacotherapy   ISSN 0277-0008   CODEN PHPYDQ 

Source / Source

Congrès
American College of Clinical Pharmacy ACCP. Winter practice anr research forum, Orlando FL , ETATS-UNIS (12/02/1995)
1995, vol. 15, n^o 1, pp. 106-125 (11 ref.), pp. 52-58

Langue / Language

Anglais

Editeur / Publisher

Pharmacotherapy, Boston, MA, ETATS-UNIS  (1981) (Revue)

Mots-clés anglais / English Keywords

Antifungal agent ; Chemotherapy ; Infection ; Leukemia ; Hemopathy ; Immunosuppression ; Oral administration ; Intravenous administration ; Bioavailability ; Pharmacokinetics ; Child ; Treatment ; Single dose ; Multiple dose ; Triazole derivatives ; Human ; Malignant hemopathy ; Immunopathology ;

Mots-clés français / French Keywords

Fluconazole ; Antifongique ; Chimiothérapie ; Infection ; Leucémie ; Hémopathie ; Immunodépression ; Voie orale ; Voie intraveineuse ; Biodisponibilité ; Pharmacocinétique ; Enfant ; Traitement ; Dose unique ; Dose répétée ; Triazole dérivé ; Homme ; Hémopathie maligne ; Immunopathologie ;

Mots-clés espagnols / Spanish Keywords

Antifúngico ; Quimioterapia ; Infección ; Leucemia ; Hemopatía ; Inmunodepresión ; Vía oral ; Vía intravenosa ; Biodisponibilidad ; Farmacocinética ; Niño ; Tratamiento ; Dosis única ; Dosis múltiple ; Triazol derivado ; Hombre ; Hemopatía maligna ; Inmunopatología ;

Localisation / Location

INIST-CNRS, Cote INIST : 19165, 35400005926812.0070